Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
5.64
-0.38 (-6.40%)
At close: Apr 28, 2026, 4:00 PM EDT
5.62
-0.02 (-0.33%)
After-hours: Apr 28, 2026, 4:07 PM EDT
Kalaris Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Kalaris Therapeutics stock have an average target of 19, with a low estimate of 14 and a high estimate of 23. The average target predicts an increase of 237.18% from the current stock price of 5.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kalaris Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Initiates $14 | Buy | Initiates | $14 | +148.45% | Apr 16, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +237.18% | Dec 23, 2025 |
| Citizens | Citizens | Buy Initiates $20 | Buy | Initiates | $20 | +254.92% | Nov 3, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +308.16% | Sep 3, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Apr 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
16.32M
EPS This Year
-2.28
from -2.85
EPS Next Year
-1.30
from -2.28
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 84.0M | ||||||
| Avg | n/a | 16.3M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.84 | 0.68 | ||||||
| Avg | -2.28 | -1.30 | ||||||
| Low | -2.51 | -2.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.